The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Chromosome 19 Annotations with Disease Speciation - A First Report from the Global Research Consortium

På svenska

Author

  • Carol L Nilsson
  • Frode Berven
  • Frode Selheim
  • Huiling Liu
  • Joseph F Moskal
  • Roger A Kroes
  • Erik P Sulman
  • Charles A Conrad
  • Frederick F Lang
  • Per E Andrén
  • Anna Nilsson
  • Elisabet Carlsohn
  • Hans Lilja
  • Johan Malm
  • David Fenyö
  • Devipriya Subramaniyam
  • Xiangdong Wang
  • Maria Gonzales-Gonzales
  • Noelia Dasilva
  • Paula Diez
  • Manuel Fuentes
  • Ákos Végvári
  • Karin Sjödin
  • Charlotte Welinder
  • Thomas Laurell
  • Thomas Fehniger
  • Henrik Lindberg
  • Melinda Rezeli
  • Goutham Edula
  • Sophia Hober
  • György Marko-Varga
Show all

Summary, in English

A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, USA, China and India, a part of the Chromosome-Centric Human Proteome Project (C-HPP) global initiative is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a sub-set with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within, and in-between these instrumental set-ups. LC-MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray, to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams in order to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples, as well as patient samples from national Biobanks.

Publishing year

2013

Language

English

Pages

135-150

Publication/Series

Journal of Proteome Research

Volume

12

Issue

1

Document type

Journal article

Publisher

The American Chemical Society (ACS)

Topic

  • Medical Engineering

Keywords

  • Proteins
  • Genes
  • Antibodies
  • mRNA
  • Mass spectrometry
  • Bioinformatics
  • Protein microarray
  • Human Disease

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1535-3893